Preclinical development of novel small molecule malaria drugs that overcome drug

克服药物障碍的新型小分子疟疾药物的临床前开发

基本信息

批准号：
8837558
负责人：
DAVID H PEYTON
金额：
$ 99.97万
依托单位：
DESIGNMEDIX, INC.
依托单位国家：
美国
项目类别：
财政年份：
2011
资助国家：
美国
起止时间：
2011-09-01 至 2017-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8837558
关键词：
Abbreviations Antimalarials Artemisinins Award Back Carrier Proteins Child Chloroquine Chloroquine resistance Clinical Research Clinical Trials Combined Modality Therapy Development Disease Dose Drug Kinetics Drug resistance Ethers Evaluation Failure Funding Gene Proteins Goals Gold Health Human Hybrids In Vitro Inhibitory Concentration 50 Institutes Intravenous Investigational Drugs Lead Lethal Dose 50 Link Malaria Monkeys Multi-Drug Resistance Mutate Neuraxis Oral Parasites Pathway interactions Pharmaceutical Preparations Pharmacodynamics Pharmacologic Substance Pharmacology Phase Plasmodium falciparum Positioning Attribute Preclinical Drug Development Preclinical Testing Predisposition Pregnant Women Property Rattus Research Contracts Resistance Small Business Technology Transfer Research Staging Structure-Activity Relationship Toxic effect Tropical Disease Universities Vacuole Verapamil artemisinine base chemosensitizing agent design drug candidate drug development flexibility forgetting in vivo innovation killings novel pre-clinical preclinical evaluation preclinical study research clinical testing resistant strain response small molecule trait vaccine development

项目摘要

DESCRIPTION (provided by applicant): The worldwide health problem created by malaria has been made more difficult by the spread of drug- resistant parasites. We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine-resistant and chloroquine-sensitive malaria. This project carries on preclinical development of a drug candidate that has been selected from this innovative class of potent antimalarials designed to overcome drug resistance. The candidate will be advanced through the ultimate stages of preclinical testing. Thus, pharmacokinetics, pharmacodynamics, pharmacology, and toxicity evaluations will be performed in both rats and monkeys. The overall goal will be completion of preclinical studies leading to approval of an Investigative New Drug (IND) application for the drug to be used in a Phase 1 human clinical trial.

描述（由申请人提供）：由于耐药寄生虫的传播，疟疾造成的全球健康问题变得更加困难。我们开发了一种口服且廉价的新型药物，可对抗氯喹耐药性和氯喹敏感型疟疾。该项目对候选药物进行临床前开发，该候选药物是从旨在克服耐药性的创新类强效抗疟药中选出的。候选人将通过临床前测试的最终阶段。因此，将在大鼠和猴子中进行药代动力学、药效学、药理学和毒性评价。总体目标是完成临床前研究，从而批准该药物用于一期人体临床试验的研究性新药 (IND) 申请。